About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Michael McTague: The pharmaceutical giants leading the market-cap parade in 2025

Michael McTague: The pharmaceutical giants leading the market-cap parade in 2025

Half of the year is over! So, which pharmaceutical giant outpaces the others? Sharp investors wonder whose market capitalization has risen farthest? Whose revenue and profit is up the most?

Let’s start with the usual suspects: Eli Lilly, Johnson & Johnson, AbbVie and NovoNordisk outrank the others by market capitalization.

The COVID-19 crisis allowed several corporations to excel mightily. The long term pattern in the market cap of these giants is quite telling. Let’s keep our focus on the last six months. Three of these behemoths have improved their market capitalization; one is going through a sharp fall.

Company Recent market cap Percent change in 2025
Eli Lilly $730 billion +3.8
Johnson & Johnson $373 billion +7.5
AbbVie $335 billion +4.7
NovoNordisk $335 billion -13.7

Eli Lilly LLY advocates can point out that the company’s value is amazing and that the +3.8% is huge given the high starting point. Johnson & Johnson JNJ rolls along boosting its value. AbbVie ABBV is also doing well.

NovoNordisk NVO is slipping. The market cap history of the creator of Ozempic looks like a peak and valley. In terms of market cap growth, it is heading for the bottom of a valley.

The Eli Lilly surge relates to a topic covered by us in a recent entry: the wide use of weight loss products. We should note: these weight loss superstars really work. The company’s massive market value indicates that weight loss success will be important for a long time.

Johnson & Johnson always finds a way to raise its value. Recently, the company announced a multiyear plan to expand research and other key areas. Obviously, investors appreciate the wise strategy.

Wilson, N.C. also appreciates it. The city is in line for a $2 billion investment from J&J, which announced last year it would build a biologics manufacturing facility there as the company  keeps moving ahead with efforts across the pharmaceutical board spanning oncology, immunology and cardiovascular disease as well as neuroscience breakthroughs and robotic surgery.

AbbVie’s latest advances include the acquisition of Nimble Therapeutics, a company which excels in oral therapies, a concept AbbVie sees as expanding their ability to reach people who suffer from autoimmune diseases.

The three giants whose market caps are rising have all made interesting strategic moves. Investors value smart action that makes the organization more competitive, especially in financially attractive areas.

The pharmaceutical market-cap loser

NovoNordisk, while still enjoying its status as Europe’s most valuable company, is watching its market value shrink because its weight loss champions, including Wegovy, may be slipping against Eli Lilly’s Zepbound. The sheer level of competition in weight loss is drawing new competitors with strong products that will likely cut into NovoNordisk’s lead.

Also worthy of note is Roche RHHBY . While its market capitalization has fallen from a high point a few years ago, it has gained nearly $50 billion this year largely thanks to its work in cardiovascular disease, a critical area.

Lunsumio, manufactured by Genentech, part of the Roche family, in combination with Polivy, also made by Genentech, reports a big improvement in progression-free survival and objective response rate compared to MabThera/Rituxan (rituximab), gemcitabine and oxaliplatin (R-GemOx), in patients suffering from lymphoma. Becoming best in class proves to be a significant factor in pumping up market capitalization.

Weight loss, oncology, cardiovascular, immunology and significant breakthroughs remain the hot areas for the industry giants. The industry continues to roll out new products, but rising corporate value comes from success in the most significant areas of patient need.

This industry has seen spectacular success in amazing solutions to big problems in wealthy countries. The battle to stay ahead rests largely on smart strategic thinking.

More from Michael McTague: Watch out for these killer superbugs

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.